

ASX Release
ASX Code: MEM

22 November 2024

CEO ADDRESS TO SHAREHOLDERS

Memphasys Limited (ASX: MEM) (“the Company”) is pleased to present the address to shareholders at the 2024 AGM.

Thank you, and good morning to our shareholders. It is a pleasure to be back in front of you and I would like to extend my welcome today and thank you for taking the time from your busy day to attend this event to engage with us and learn more about our Company

Whilst 2024 has continued to be a year of change, challenge and new beginnings it was also a year of significant achievement. Throughout the period, our goal remained to build long-term sustainable value and position Memphasys for future success. Overall, I am proud of what we have accomplished and what we are building.

Our strategy actions have been to:

- Reduce operating costs and divert those funds into areas that could result in ROI.
- Develop the first working RoXsta prototype.
- Explore animal health initiatives in both Felix and Oxidative Stress.
- Put strategies in place that will likely end the Felix trial at the end of 2024.
- Position Felix for faster regulatory and commercial access in higher value markets.
- Explore possible commercial partnerships with other commercial entities.

I believe that we now have the right building blocks in place to achieve these goals.

Since I took up the role, I have been listening to what is top of mind for our customers, shareholders, people and regulators. This process has been invaluable and reiterates the importance of gathering shareholder insights. This has helped to shape our strategy.

Having said that 2025 will continue to be another big year of change and transformation but I am confident we now have the team to deliver our strategy. The focus of which will be to develop a solid funding model that will provide the necessary runway to see Felix to market and continue to bring RoXsta closer to commercialisation with high applications in high value markets.

With your support and feedback, we will continue to execute the strategies with agility and determination. Finally, I would like to thank all The Memphasys executive team and board for their hard work in 2024, but by far the majority of the accolades goes out to you the shareholders who have supported the company time and time again. Without you none of this would be possible.

Thank you, I look forward to a productive and successful finish to 2024 and an equally as eventful 2025.

David Ali
Managing Director and CEO

This announcement has been approved for release by the Board of Memphasys Limited.

ENDS

For further information, please contact:

Dr David Ali
Managing Director & CEO
Memphasys Limited
Tel: +61 2 8415 7300
E: david.ali@memphasys.com

About Memphasys

Memphasys Limited (ASX: MEM) specialises in reproductive biotechnology for high value commercial applications. Reproductive biotechnology products in development include medical devices, in vitro diagnostics, and new proprietary media. The Company's patented bio separation technology, utilised by the Company's most advanced product, the Felix™ System, combines electrophoresis with proprietary size exclusion membranes to separate the most viable sperm cells for human artificial reproduction.

Website: www.memphasys.com

The Felix™ System is a registered trademark of Memphasys Limited. All rights reserved.